Absci Corp (ABSI): Cash & Equivalents

Annual figures by period end, from SEC filings.

$20.02M
As of 2025-12-31
$107.86M
As of 2026-06-30
-30.6%
3-year compound annual growth
-22.1%
5-year compound annual growth
$252.57M2020-12-31: $69.87M2021-12-31: $252.57M2022-12-31: $59.95M2023-12-31: $72.36M2024-12-31: $41.21M2025-12-31: $20.02M$20.02M
2020-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$20.02M-51.4%2026-03-24, Balance as of period end
2024-12-31$41.21M-43.0%2026-03-24, Balance as of period end
2023-12-31$72.36M+20.7%2025-03-18, Balance as of period end
2022-12-31$59.95M-76.3%2024-03-21, Balance as of period end
2021-12-31$252.57M+261.5%2023-03-30, Balance as of period end
2020-12-31$69.87Mn/a2022-03-22, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Absci Corp (ABSI)2025-12-31$20.02M-51.4%
iSpecimen Inc. (ISPC)2025-12-31$6.88M+266.3%
OneMedNet Corp (ONMD)2025-12-31$585.0K+240.1%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$6.45M+483.5%
Foxo Technologies Inc. (FOXO)2025-12-31$207.5K+203.9%
OmniAb, Inc. (OABI)2025-12-31$25.52M-7.5%
MaxCyte, Inc. (MXCT)2025-12-31$20.07M-28.0%
NRC Health (NRC)2025-12-31$4.14M-2.2%
Medpace Holdings, Inc. (MEDP)2025-12-31$497.05M-25.8%

Compare ABSI, ISPC, ONMD, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗